Please login to the form below
AndroGel
This page shows the latest AndroGel news and features for those working in and with pharma, biotech and healthcare.
AbbVie sales jump on strong Humira gains
Among other products, HIV therapy Kaletra (lopinavir/ ritonavir) rose 1.1 per cent to $278m, while revenue from testosterone replacement therapy AndroGel fell 6.5 per cent to $258m.
Latest news
-
Pay-for-delay deals 'sometimes violate antitrust law'
involving testosterone replacement therapy product AndroGel should be allowed to go forward.
-
AbbVie expects Humira to drive growth in inaugural guidance
Top of the list in the speciality division is testosterone replacement therapy AndroGel – 31 per cent to $1.15bn in 2012 – with support from Creon (pancrelipase) for pancreatic insufficiency and hypothyroidism
-
Abbott plans Solvay layoffs
Solvay's product portfolio includes the testosterone gel AndroGel, the progesterone capsule Prometrium, and the pancreatic enzyme replacement therapy Creon (pancreatin).
More from news
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Pharma deals in May 2015
This is not the first such case for Teva, as the FTC also filed suit last September for an alleged pay for delay relating to AndroGel.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
-
Account Executive
-
Salary TBC
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
-
Account Supervisor
-
Salary TBC
- Entry Level Editorial Assistant – Medical Education –Buckinghams...
-
Highly Competitive
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Scientific Director - Medical Communications - Berkshire
-
Excellent package on offer
- Senior Editor - Medical Communications - South East - Buckingham...
-
Highly competitive salary &package
-
Account Director
-
Salary TBC
Subscribe to our email news alerts
- Genital herpes vaccine candidate heads for human studies
- Roche’s Spinraza, Zolgensma rival risdiplam hits the mark in SMA
- FDA advisors say no to empagliflozin in type 1 diabetes
- Novartis makes case for NASH candidate tropifexor
- MSD hangs ‘for sale’ sign on French facility, shedding 207 staff
- AbbVie sells $30bn of bonds ahead of Allergan merger
- What do Healthcare Professionals think about the inclusion of remote selling techniques?
- Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day
- BeiGene bags FDA approval for first product Brukinsa in lymphoma
- Amarin wins FDA advisory nod for Vascepa cardiovascular expansion
- Shionogi scores FDA approval for new cUTI antibiotic
- Merck acquires pre-clinical biotech Calporta for up to $576m
PMHub
Page & Page
Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...
Latest intelligence
- What do Healthcare Professionals think about the inclusion of remote selling techniques?
- Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
- Strengthening business competition and reducing anti-competitive practices
- How the CMA is tackling high prices for essential drugs...
- Pharmaceutical innovation in the APAC region
- A first-of-its-kind study paints a vivid picture of the APAC region’s future...
Quick links
Infographics
